

Dear Healthcare Professional,

Thank you for your unsolicited request for information. Accompanying this letter is the following information you requested on YUTIQ[®] (fluocinolone acetonide intravitreal implant) 0.18 mg. If we can be of any further assistance, please contact our Medical Information department at 844-445-8843 between the hours of 9:00 AM to 8:00 PM ET (6:00 AM to 5:00 PM PT), Monday through Friday or via email at yutiqmedinfo@anipharma.com.

YUTIQ is indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.

YUTIQ is contraindicated in patients with active or suspected ocular or periocular infections including most viral disease of the cornea and conjunctiva including active epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial infections and fungal diseases.

YUTIQ is contraindicated in patients with known hypersensitivity to any components of this product.

Please see the enclosed YUTIQ Prescribing Information (PI) for detailed information including Warnings and Precautions and Adverse Reactions as well as the appropriate use of YUTIQ.

This communication may contain confidential, proprietary, and/or privileged information. It is intended solely for the use of the addressee. If you are not the intended recipient, you are strictly prohibited from disclosing, copying, distributing or using any of this information. If you received this communication in error, please contact the sender immediately and destroy the material in its entirety, whether electronic or hard copy.

Thank you for your inquiry.

Sincerely,



Steve Wu, PharmD
ANI Pharmaceuticals Medical Information

Administration of Multiple YUTIQ[®] Intravitreal Implants

Abstract

- This document provides summary information pertaining to YUTIQ[®] (fluocinolone acetonide [FAc] intravitreal implant) 0.18 mg and its indication for use in the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye
- This document outlines the use of YUTIQ as a single injection per treatment period

Note that this document is for information purposes only and has been sent as a professional courtesy to provide you with data to assist in making your own practicing decisions. Please refer to the YUTIQ (fluocinolone acetonide [FAc]) implant USPI for full [Prescribing Information](#) and safety information. ANI Pharmaceuticals does not recommend the use of its products in any manner inconsistent with the FDA-approved labeling. If you have further questions, please contact the Medical Affairs Department at <drugsafety@anipharmaceuticals.com>.

To report an adverse event for any ANI Pharmaceuticals product, please call 1-800-308-6755 or contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Email: <drugsafety@anipharmaceuticals.com>

Introduction

Clinical Background

YUTIQ (FAc intravitreal implant) 0.18 mg is indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.¹

Composition of YUTIQ

YUTIQ is a non-bioerodible intravitreal implant in a drug delivery system containing 0.18 mg FAc, designed to release FAc at an initial rate of 0.25 mcg/day, and lasting 36 months. Each YUTIQ consists of a light brown 3.5mm x 0.37mm implant containing 0.18 mg of the active ingredient FAc and the following inactive ingredients: polyimide tube, polyvinyl alcohol, silicone adhesive, and water for injection.¹

Clinical Pharmacology

YUTIQ contains the corticosteroid FAc. Corticosteroids inhibit inflammatory responses to a variety of inciting agents including multiple inflammatory cytokines. They inhibit edema, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, fibroblast proliferation, deposition of collagen, and scar formation associated with inflammation. Corticosteroids are thought to act by inhibition of phospholipase A₂ via induction of inhibitory proteins collectively called lipocortins. It is postulated that these proteins control biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting release of the common precursor, arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A₂.¹

Response to Information Request

YUTIQ is designed as a single intravitreal injection. The use of multiple YUTIQ implants has not currently been studied in clinical trials.¹

Reference

1. YUTIQ (fluocinolone acetonide intravitreal implant) 0.18 mg, for intravitreal injection. Prescribing Information. ANI Pharmaceuticals, Inc. Updated 2023. Accessed January 17, 2025. <https://yutiq.com/pi/>